Physician profile
Stephen E Gist
NPI 1770555450
$2,500.77
in general payments reported to CMS, 2019-2025
30 companies · $615 in 2025
The $615 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $59.80 · 2021: $208 · 2022: $450 · 2023: $443 · 2024: $493 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $594.49 | 2019-2025 | |
| Abbvie INC. | $293.96 | 2021-2025 | |
| Novo Nordisk INC | $279.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $147.28 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $147.18 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.98 | 2019-2025 | Jardiance, Jascayd |
| Astellas Pharma US INC | $124.43 | 2019-2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $115.06 | 2019-2024 | Farxiga |
| Abbott Laboratories | $95.44 | 2025 | Freestyle Libre 3, Eterna, Esprit |
| Madrigal Pharmaceuticals | $54.03 | 2024-2025 | Resmetirom, Rezdiffra |
| Sumitomo Pharma America, INC. | $49.87 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.90 | 2022-2023 | Xifaxan |
| Amarin Pharma, INC. | $39.85 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $38.25 | 2022-2023 | Oxlumo |
| Exact Sciences Corporation | $32.73 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $30.45 | 2023 | Quviviq |
| Inari Medical, INC. | $28.21 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi Pasteur INC. | $28.21 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $27.46 | 2023 | |
| Lilly USA, LLC | $26.19 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.07 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $21.99 | 2024 | |
| Renalytix Ai, INC. | $15.98 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Vbi Vaccine (Delaware) INC. | $15.72 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.70 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $14.31 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.24 | 2021 | |
| Antares Pharma, INC. | $14.22 | 2025 | Xyosted |
| Merck Sharp & Dohme LLC | $13.10 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Gist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.